



UNIVERSITI PUTRA MALAYSIA

***ANTINOCICEPTIVE PROFILE OF A SYNTHETIC CURCUMINOID  
DERIVATIVE 2,6-BIS-(4-HYDROXY-3-METHOXY-BENZILIDINE)-  
CYCLOHEXANONE IN MURINE MODEL OF INDUCED-NOCICEPTION***

LEE MING TATT

FPSK(p) 2013 11

**ANTINOCICEPTIVE PROFILE OF A SYNTHETIC CURCUMINOID  
DERIVATIVE 2,6-BIS-(4-HYDROXY-3-METHOXY-BENZILIDINE)-  
CYCLOHEXANONE IN MURINE MODEL OF INDUCED-NOCICEPTION**



Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in  
Fulfillment of the Requirements for the Degree of Doctor of Philosophy

**February 2013**

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

**ANTINOCICEPTIVE PROFILE OF A SYNTHETIC CURCUMINOID DERIVATIVE 2,6-BIS-(4-HYDROXY-3-METHOXY-BENZILIDINE) CYCLOHEXANONE IN MURINE MODEL OF INDUCED-NOCICEPTION**

By

**LEE MING TATT**

**February 2013**

**Chairman: Professor Mohd. Roslan Sulaiman, PhD**

**Faculty: Faculty of Medicine and Health Sciences**

**Introduction:** The present study investigated the antinociceptive potential of a synthetic curcuminoid derivative, 2,6-bis-4-(hydroxyl-3-methoxybenzilidine)-cyclohexanone, or BHMC in pain-induced models in mice. **Problem statement:** Pain is a major symptom of various diseases that persists to produce severe physical and psychological distress for many patients. However, current treatment for pain produced undesirable adverse effects thus limited their use. This has led to a search for new pharmacologically potent antinociceptive compounds with minimum or no adverse effects. **Objective:** The present study aimed to investigate the systemic, peripheral and supraspinal antinociceptive potential of BHMC in pain models in mice. The research project also aimed to further investigate the possible mechanism of action in systemic, peripheral and supraspinal antinociceptive effect of BHMC. **Methodology:** Systemic antinociceptive effect of

BHMC was determined using acetic acid-induced abdominal constriction test, formalin induced-paw licking test and hotplate test. The systemic effect of BHMC was also evaluated via chronic constriction injury-induced neuropathic pain in mice. Peripheral and supraspinal antinociceptive effect of BHMC was evaluated via carrageenan-induced hyperalgesia test and thermal-induced nociception test, respectively. **Results and discussion:** It was demonstrated that systemic treatment of BHMC exhibited dose-dependent inhibitory effect in chemical- and thermal-induced nociception. Further investigation on the involvement of descending modulatory pathway in systemic antinociceptive effect of BHMC showed that BHMC selectively activated  $\kappa$ -opioid, A<sub>1</sub>-adenosine, D<sub>2</sub>-dopamine, M-acetylcholine, GABA<sub>B</sub>,  $\alpha_2$ -noradrenaline and 5-HT<sub>A1</sub> receptors. Activation of these inhibitory receptors triggered the efflux of potassium ion from nociceptive neuron, leading to neuronal hyperpolarisation. Hyperpolarisation of nociceptive neuron via nitric oxide (NO) independent cyclic guanosine monophosphate (cGMP) induced potassium (K<sup>+</sup>) channel opening was shown as one of the possible antinociceptive mechanism of systemic antinociceptive action of BHMC. Dose-dependant inhibitory effect of BHMC was also shown in CCI-induced hyperalgesia test in mice, which indicated a similar mechanism of action in BHMC-induced antinociception. It was also demonstrated that peripheral and supraspinal administration of BHMC produced dose-dependent antinociceptive effect, with peripheral antinociceptive effect of BHMC was via  $\mu$ -, $\kappa$ -opioid receptor and NO-independent cGMP/protein kinase G (PKG)/K<sup>+</sup> channel activation; whereas supraspinal analgesic effect of BHMC was through  $\kappa$ -opioid/NO/cGMP/PKG/K<sup>+</sup> channel activation. **Conclusion:** The present study demonstrated that BHMC possessed potential systemic, peripheral and supraspinal antinociceptive effect

through mechanisms that caused the activation of K<sup>+</sup> channels leading to neuronal membrane hyperpolarisation.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai  
memenuhi keperluan untuk ijazah Doktor Falsafah

**KAJIAN KESAN ANTINOSISEPTIF 2,6-BIS-4-(HIDROKSI-3-METHOXYBENZYLIDINE)-CYCLOHEXANONE TERHADAP MODEL NOSISEPSI MENCIT**

Oleh

**LEE MING TATT**

**Februari 2012**

**Pengerusi : Profesor Mohd. Roslan Sulaiman, PhD**

**Fakulti: Fakulti Perubatan dan Sains Kesihatan**

**Pengenalan:** Projek ini telah dijalankan untuk mengkaji kesan antinosiseptif satu sebatian sintetik analog kurkumin, 2,6-bis-4-(hidroksi-3-methoxy-benzilidine)-cyclohexanone atau BHMC ke atas model mencit yang diaruh kesakitan.

**Penyataan masalah:** Sakit merupakan simptom utama bagi kebanyakan penyakit yang sekiranya berkekalan boleh menyebabkan tekanan fizikal dan psikologi yang serius kepada pesakit. Walaubagaimana pun, rawatan terkini untuk sakit menghasilkan kesan-kesan sampingan tidak dikehendaki yang mengehadkan penggunaannya. Oleh sebab itu, kajian bagi mencari sebatian antinosiseptif yang berkesan secara farmakologikal dengan kesan sampingan yang minimal atau langsung tiada kesan sampingan. **Objektif:** Tujuan utama projek ini adalah untuk mengkaji potensi BHMC sebagai sebatian yang mempunyai kesan antinosiseptif secara sistemik, periferi dan supraspinal dengan menggunakan model model kajian kesakitan dalam mencit.. Projek ini juga bertujuan untuk mengkaji mekanisme

tindakbalas BHMC yang berkemungkinan dalam memberi kesan antinosiseptif secara sistemik, periferi dan supraspinal. **Metodologi kajian:** Kajian kesan antinosiseptif BHMC dijalankan dengan menggunakan ujian kekecutan otot abdomen aruhan asid asetik, ujian penjilatan tapak kaki aruhan formalin dan ujian plat panas. Efikasi kesan sistemik BHMC juga dikaji menggunakan model sakit neurogenik dalam mencit. Kesan antinosiseptif periferi dan supraspinal BHMC dinilai melalui ujian hiperalgesia aruhan carrageenan dan ujian nosisepsi aruhan haba. **Keputusan dan perbincangan:** BHMC menunjukkan aktiviti antinosiseptif sistemik berkadar dos ke atas ujian pengecutan otot abdomen aruhan asid asetik, ujian penjilatan tapak kaki aruhan formalin dan ujian plat panas. Kajian lanjutan menunjukkan BHMC mengaktifkan reseptor  $\kappa$ -opioid, A<sub>1</sub>-adenosine, D<sub>2</sub>-dopamine, M-acetylcholine, GABA<sub>B</sub>,  $\alpha_2$ -noradrenaline dan 5-HT<sub>A1</sub>. Tambahan pula, mekanisme antinosiseptif sistemik BHMC adalah melalui hiperpolarisasi saraf nosiseptif oleh pengaktifan saluran kalium ( $K^+$ ) melalui siklik guanosin monofosfat (cGMP) tanpa nitrik oxida (NO). Mekanisme yang sama juga ditunjukkan dalam kesan antinosiseptif BHMC terhadap model sakit neuropatik dalam mencit. Kajian antinosiseptif periferi and supraspinal BHMC menunjukkan bahawa BHMC memberi kesan perencatan berkadar dos ke atas ujian hiperalgesia induksi carrageenan dan ujian nosisepsi aruhan haba, masing masing. Kajian mekanisme antinosiseptif periferi menunjukkan bahawa BHMC mengaktifkan saluran  $K^+$  melalui cGMP/protein kinase G (PKG) tanpa NO dan reseptor  $\mu$ - serta  $\kappa$ -opioid. Kajian antinosiseptif secara supraspinal BHMC menunjukkan bahawa memberi kesan perencatan berkadar dos ke atas ujian ujian nosisepsi induksi haba dan mekanisme antinosiseptif secara supraspinal adalah melalui pengaktifan saluran  $K^+$  melalui NO/cGMP/PKG dan reseptor  $\kappa$ -

opioid. **Kesimpulan:** Projek ini membuktikan aktiviti antinosiseptif BHMC berlaku melalui sistemik, periferi dan supraspinal menerusi mekanisma yang membawa kepada pengaktifan saluran  $K^+$  yang membawa kepada hiperpolarisasi sel membran saraf.



## **ACKNOWLEDGEMENT**

First and foremost I would like to thank the chairman of my supervisory committee, Prof. Dr. Mohd. Roslan Sulaiman for his invaluable support for all these years and members of my supervisory committee Prof. Dr. Daud Ahmad Israf Ali and Prof. Dr. Md. Nordin. Hj. Lajis for their advices throughout my candidature. I would like to also express my gratitude to fellow laboratory seniors, Dr. Tham Chau Ling, Dr. Enoch Kumar Perimal, Dr Ahmad Akira, Dr Tengku Azam Shah Tengku Mohammad, Mr Mohamed Haneif Khalid, Ms Syamimi Khalid, Ms Ong Hui Ming for their support during the research period. And also not forgetting the cheerful laboratory mates of mine that accompanied me through the postgraduate life, Mdm Norazreen Ismail, Ms. Revathee Rajajendrem, Ms. Jacklin Suloon, Ms Nur' Adilah Makthar, Mdm Noor Azlina Abu Bakar, Ms Nur Izzati Ismail, Ms Nurhayatie Samsul Baharil, Ms Nor Asmara Tasrip, Mr. Mohd Nasier Kamaldin, Mr Lee Yu Zhao, Ms. Chung Pui Ping, Mdm Khairunnisa Azni, Ms Yeoh Sin Yee, Ms Tan Min Wai, Mr Teo Jun Fook, Mr Low Chin Tuan, Miss Elain Chin Jinfeng and many many more.

I certify that a Thesis Examination Committee has met on 8th of February 2013 to conduct the final examination of Lee Ming Tatt on his thesis entitled "Antinociceptive Profile of a Synthetic Curcuminoid Derivative, 2,6 bis-(4-hydroxy-3-methoxy-benzilidine)-cyclohexanone on Murine Model of Induced-nociception" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Examination Committee were as follows:

**Zuraini binti Hj Ahmad, PhD**

Associate Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Chairman)

**Abdul Manan bin Mat Jais, PhD**

Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Internal Examiner)

**Mohamad Taufik Hidayat bin Baharudin, PhD**

Senior Lecturer

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Internal Examiner)

**Erdem Yesilada, PhD**

Professor

Department of Pharmacognosy, Faculty of Pharmacy

Yeditepe University

Turkey

(External Examiner)

---

**SEOW HENG FONG, PhD**

Professor and Deputy Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 21 March 2013

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

**Mohd. Roslan Sulaiman, PhD**

Professor

Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Daud Ahmad Israf Ali, PhD**

Professor

Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Md. Nordin Hj. Lajis, PhD**

Professor

Institute of Biosciences  
Universiti Putra Malaysia  
(Member)

---

**BUJANG BIN KIM HUAT, PhD**

Professor and Dean

School of Graduate Studies  
Universiti Putra Malaysia

Date:

## **DECLARATION**

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.

**LEE MING TATT**

Date: 8 February 2013



## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	ii
<b>ABSTRACT</b>	v
<b>ACKNOWLEDGEMENTS</b>	viii
<b>APPROVAL</b>	ix
<b>DECLARATION</b>	xi
<b>LIST OF TABLES</b>	xvi
<b>LIST OF FIGURES</b>	xvii
<b>LIST OF ABBREVIATION</b>	xx
<b>LIST OF ANNOTATION</b>	xxii
 <b>CHAPTER</b>	
1 <b>INTRODUCTION</b>	1
1.1 General Objective	4
1.2 Specific Objectives	4
1.3 Hypothesis	5
2 <b>LITERATURE REVIEW</b>	6
2.1 Nociception	6
2.1.1 Depolarisation of neuron and pain	8
2.1.2 Hyperpolarisation of neuron and analgesia	8
2.2 Molecular pathways of pain	9
2.2.1 Mediators of Pain	10
2.2.1.1 Glutamate	10
2.2.1.2 Substance P	12
2.2.1.3 Prostaglandin E <sub>2</sub>	12
2.2.1.4 Bradykinin	14
2.3 Molecular pathways of Analgesia	16
2.3.1 Descending pain modulatory system	16
2.3.2 NO/cGMP/PKG signalling pathway	22
2.3.3 Potassium ion channels	24
2.4 Analgesic Agents	27
2.4.1 Current pain therapy	27
2.4.1.1 Opioids	28
2.4.1.2 Non-steroidal anti-inflammatory drugs	29
2.4.1.3 Analgesic Adjuvants	30
2.4.2 Limitation of current pain therapy	31
2.4.3 Discovery of novel analgesic agents	32
2.4.3.1 Natural product-based drug discovery	33
2.4.3.2 Analogue-based drug discovery	34
2.4.4 2,6-bis-4-(hydroxyl-3-methoxy-benzilidene)-cyclohexanone	34
2.4.4.1 BHMC as a curcuminoid derivative	35
2.4.4.2 BHMC as a benzilidine cyclohexanone derivative	37
2.4.4.3 Therapeutic potentials of BHMC	38

<b>3</b>	<b>INVESTIGATION ON SYSTEMIC ANALGESIC EFFECT OF 2,6-BIS-4-(HYDROXY-3-METHOXY- BENZILIDINE)-CYCLOHEXANONE AND ITS POSSIBLE MECHANISM(S) OF ACTION</b>	<b>40</b>
3.1	Introduction	40
3.2	Materials and Method	41
3.2.1	Synthesis of BHMC	41
3.2.2	Chemicals	41
3.2.3	Animals	42
3.2.4	Evaluation of antinociceptive property of BHMC	43
3.2.4.1	Acetic acid induced abdominal constriction test	43
3.2.4.2	Formalin-induced paw licking test	43
3.2.4.3	Hot-plate test	44
3.2.4.4	Rotarod test	45
3.2.5	Possible mechanism(s) of systemic analgesia of BHMC	46
3.2.5.1	Involvement of descending modulatory system	46
3.2.5.2	Involvement of the NO/cGMP/ $K_{ATP}$ channel signaling pathway	49
3.2.6	Acute toxicity assessment	50
3.2.7	Statistical analysis	50
3.3	Results	51
3.3.1	Acetic acid induced abdominal constriction test	51
3.3.2	Formalin induced paw licking test	52
3.3.3	Hotplate test	54
3.3.4	Rotarod test	56
3.3.5	Possible mechanism(s) of systemic analgesia of BHMC	57
3.3.5.1	Involvement of descending modulatory system	57
3.3.5.2	Involvement of the NO/cGMP/ $K_{ATP}$ channel signaling pathway	66
3.3.6	Acute toxicity assessment	67
3.4	Discussion	67
3.5	Conclusion	73
<b>4</b>	<b>INHIBITORY EFFECT OF OF 2,6-BIS-4-(HYDROXY- 3-METHOXY-BENZILIDINE)-CYCLOHEXANONE ON NEUROPATHIC PAIN-INDUCED HYPERALGESIA AND ITS POSSIBLE MECHANISM(S) OF ACTION</b>	<b>74</b>
4.1	Introduction	75
4.2	Material and Methods	75
4.2.1	Synthesis of BHMC	75
4.2.2	Chemicals	75
4.2.3	Animals	76

4.2.4	Chronic constriction injury (CCI) surgical procedure	76
4.2.5	CCI-induced mechanical hyperalgesia	77
4.2.6	Involvement of opioid receptors	77
4.2.7	Involvement of the NO/cGMP/K <sub>ATP</sub> channel signalling pathway	78
4.2.8	Statistical analysis	79
4.3	Results	79
4.3.1	CCI-induced mechanical hyperalgesia	80
4.3.2	Involvement of opioid receptor	82
4.3.3	Involvement of NO/cGMP/K <sub>ATP</sub> channel signaling pathway	83
4.4	Discussion	86
4.5	Conclusion	
<b>5</b>	<b>INVESTIGATION ON PERIPHERAL ANALGESIC EFFECT OF 2,6-BIS-4-(HYDROXY-3-METHOXY-BENZILIDINE)-CYCLOHEXANONE AND ITS POSSIBLE MECHANISM(S) OF ACTION</b>	<b>87</b>
5.1	Introduction	87
5.2	Material and Methods	88
5.2.1	Synthesis of BHMC	88
5.2.2	Chemicals	88
5.2.3	Animals	88
5.2.4	Carrageenan-induced hyperalgesia test	88
5.2.5	Pain mediators-induced hyperalgesia test	89
5.2.6	Involvement of opioid receptors	90
5.2.7	Involvement of the NO/cGMP/PKG pathway	90
5.2.8	Involvement of K <sup>+</sup> channels	91
5.2.9	Statistical analysis	91
5.3	Results	92
5.3.1	Carrageenan-induced hyperalgesia test	92
5.3.2	Pain mediators-induced hyperalgesia test	94
5.3.3	Involvement of opioid receptors	95
5.3.4	Involvement of the NO/cGMP/PKG pathway	97
5.3.5	Involvement of K <sup>+</sup> channels	99
5.4	Discussion	101
5.5	Conclusion	107
<b>6</b>	<b>INVESTIGATION ON SUPRASPINAL ANALGESIC EFFECT OF 2,6-BIS-4-(HYDROXY-3-METHOXY-BENZILIDINE)-CYCLOHEXANONE AND ITS POSSIBLE MECHANISM(S) OF ACTION</b>	<b>108</b>
6.1	Introduction	108
6.2	Material and methods	109
6.2.1	Synthesis of BHMC	109
6.2.2	Chemicals	109
6.2.3	Animals	109

6.2.4 Intracerebroventricular administration protocol	109
6.2.5 Thermal-induced nociception test	110
6.2.6 Involvement of opioid receptor	110
6.2.7 Involvement of the NO/cGMP/PKG pathway	111
6.2.8 Involvement of K <sup>+</sup> channels	111
6.2.9 Statistical analysis	112
6.3 Results	113
6.3.1 Thermal-induced nociception test	113
6.3.2 Involvement of opioid receptor	115
6.3.3 Involvement of the NO/cGMP/PKG pathway	117
6.3.4 Involvement of K <sup>+</sup> channels	119
6.4 Discussion	121
6.5 Conclusion	124
<b>7 SUMMARY, CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH</b>	<b>125</b>
<b>REFERENCES</b>	<b>129</b>
<b>BIODATA OF STUDENT</b>	<b>148</b>
<b>LIST OF PUBLICATIONS/PROCEEDINGS/AWARDS</b>	<b>149</b>